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Conference 2010: Washington, DC, September 21–25, 2010Jack C. J. Sun, MD, MSc, Ravi K. Ghanta, MD, and Michael J. Davidson, MDThe Twenty-second Annual Transcatheter Cardiovascular
Therapeutics (TCT) conference was held in Washington,
DC, from September 21 to 25, 2010. Sponsored by the
Cardiovascular Research Foundation, this is the largest
interventional cardiovascular conference in the world with
customized programs for interventional cardiologists, radi-
ologists, cardiac surgeons, and vascular surgeons. With the
exponential growth of catheter-based cardiac and vascular
treatments, the relevance to and impact of the conference
on the practice of cardiothoracic and vascular surgeons is
ever increasing. The results of clinical trials presented at
the conference that hold a specific interest for cardiac
surgeons are the focus of this report.TRANSCATHETER VALVE THERAPIES
Aortic Valve Replacement
Edwards SAPIEN valve (first generation with Ascendra
delivery system [Edwards Lifesciences, Inc, Irvine,
Calif]). Arguably the most high-profile clinical study
presented at the TCT this year was the initial cohort of
the landmark Placement of AoRTic TraNscathetER Valve
(PARTNER) clinical trial. This represents the first US
randomized percutaneous aortic valve trial. Two cohorts
of patients were evaluated for the PARTNER trial: cohort
A compared surgical aortic valve replacement versus trans-
catheter aortic valve implantation (TAVI) among high-risk
operative candidates whereas cohort B examined outcomes
in inoperable patients. The cohort B results were presented
at TCT, whereas cohort A results were anticipated in April
2011. Cohort B randomized 358 patients with symptomatic,
severe aortic stenosis not suitable for surgical therapy to ei-
ther TAVI (n ¼ 179) or standard medical therapy, including
possible balloon valvuloplasty (n ¼ 179).1
The primary end point of all-cause mortality at 1 year was
significantly lower in the TAVI group than in the standard
therapy group (30.7% vs 49.7%; P<.001) with a corre-
sponding number-needed-to-treat to prevent 1 death of 5.
Composite end points of all-cause mortality, repeat hospi-
talization, and stroke at 1 year were also significantly lowerFrom the Division of Cardiac Surgery, Brigham & Women’s Hospital Harvard
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report was recently published.2
Previous data from the Canadian Edwards TAVI Multi-
center Registry of 339 patients receiving either transfemoral
(TF) (n¼ 162) or transapical (TA) (n¼ 177) TAVI revealed
that procedural mortality was similar (1.8% TF vs 1.7%
TA) but significantly lower in the TF group when extended
out to 30 days (9.9% vs 11.3%). New data from extended
follow-up show that at 2 years, survival in both groups
equalized at approximately 68%, and predictors of late
mortality include chronic obstructive pulmonary disease,
Society of Thoracic Surgeons score, chronic renal insuffi-
ciency, and periprocedural sepsis.3
The PARTNER-EU registry of 61 TF and 69 TA patients
showed decreased mortality in the TF group (8% vs 19%)
with survival curves continuing to diverge at 18 months in
favor of the TF patients (29% TF mortality vs 57% TA
mortality).4
Two cohorts from the SOURCE registry5 were presented:
the first consisting of 1123 patients enrolled betweenNovem-
ber 2007 and January 2009 from 32 centers; the second
consisting of 1306 patients enrolled between February and
December 2009 from 38 centers. TF patient mortality
decreased from cohort 1 to cohort 2 whereas TA mortality
remained stable in both cohorts at 30 days. It was noted that
risk scores were lower in cohort 2, which may help explain
the improved results. Mortality for both cohorts at 30 days
was 7.5% in the TF group and 10.7% in the TA group.5
Walther6 from Leipzig presented the outcomes of a large
cohort of 357 TA TAVI patients. Thirty-day mortality was
8.1%, stroke 0.5%, and need for permanent pacemaker
4.5%. There was an 11% incidence of periprocedural
complications that was associated with a 30% mortality.
Survival at 1 and 2 years was 73% and 68%, respectively.
Webb7 from Vancouver presented results of transcatheter
valve replacement in patients with pre-existing stented
valves (‘‘valve-in-valve’’). The cohort of 29 patients con-
sisted of 13 with prosthetic mitral valves, 11 with prosthetic
aortic valves, 3 with prosthetic pulmonic valves, and 2 with
prosthetic tricuspid valves. Almost all valve replacements
were performed via the TA approach with the exception
of tricuspid valves, which were implanted through a transat-
rial approach. Note was made that the minimum size of the
stented prosthetic valve was 23 mm to accommodate a SA-
PIEN valve and achieve acceptable gradients. Thirty-day
mortality for this small cohort was 7%.
The COMPASSION-US trial8 looked at 30 patients with
previous tetralogy of Fallot repair or Ross procedure whoery c August 2011
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stenosis and were treated with transcatheter pulmonic
SAPIEN valve implantation. The mean age of these patients
was 31 years and survival at 1 year was 92.3%.
The preliminary results of the PREVAIL-EU9 study of
150 patients who received TF TAVI using the new SAPIEN
XT valve with the smaller 18F NovaFlex delivery device
(Edwards Lifesciences) was presented. These patients had
Society of Thoracic Surgery risk scores of greater than 10
or log EuroSCOREs of greater than 20. The first 93 patients
had a mortality incidence of 8.6%, stroke incidence of
3.2%, and vascular complication incidence of 12.9%. Re-
sults for the full cohort of 150 patients should be available
by fall of 2011.9
Medtronic CoreValve (Medtronic, Inc, Minneapolis,
Minn). Preliminary results of 118 patients (375 planned)
from 10 centers from the Australia–New Zealand Med-
tronic CoreValve Registry10 revealed a 96% procedural
success rate with 30-day incidences of mortality 5.6%,
stroke 1.9%, and permanent pacemaker requirement 40%.
A safety and efficacy study of the next generation of the
18F Medtronic CoreValve also had its preliminary results
reported for the first 88 patients. An 18% mortality at 30
days and 28%mortality at 1 year were reported.11 Random-
ized controlled trials of TAVI using the 18F CoreValve have
started in both Europe (SURTAVI)12 and in the United
States with the US Pivotal Trial13 recently approved by
the Food and Drug Administration.
New and upcoming TAVI devices. First-in-man safety
and efficacy studies in small series of patients were pre-
sented for several new TAVI devices including the Direct
Flow Medical percutaneous aortic valve (Direct Flow
Medical, Inc, Santa Rosa, Calif), the Sadra Medical Lotus
Valve System (Sadra Medical, Inc, Los Gatos, Calif), the
Medtronic Ventor Engager transapical valve (Medtronic),
the Jena transapical valve (JenaValve Technology GmbH,
Munich, Germany), the Symetic Accurate transpical valve
(Symetic Inc, Switzerland), and the Heart Leaflet Technol-The Journal of Thoracic and Caogies system (Heart Leaflet Technologies, Inc, Maple
Grove, Minn).
St Jude Medical, Inc (St Paul, Minn), unveiled its new
transcatheter valves, which consist of both bovine and por-
cine pericardial valves on a nitinol self-expanding stent that
will be repositionable and retrievable. There will be an 18F
TF system and a 24F sheathless-design TA system. The TF
system can be resheathed after up to 95% deployment of the
valve. A European trial is planned for 2011 and a US trial
for 2012-2113.14Mitral Valve Repair
In contrast to the large clinical trial results from TAVI,
adoption of transcatheter mitral repair technology has
lagged. Nevertheless, trial updates for several transcatheter
mitral technologies, including annuloplasty and edge-to-
edge repair, were presented.
Coronary sinus annuloplasty devices. The EVOLUTION
II prospective observational study/case series using the
Edwards MONARC device reported preliminary results
with 52 patients; device placement was planned for 34 of
them and medical therapy for 18. Of the 34 patients in
whom device placement was planned, 30 were successfully
implanted with 30-day incidences of mortality of 3.3% and
myocardial infarction 3.3%. Mortality at 6 months for
device patients was 4.2%. The primary end point of 1 grade
or more decrease in mitral regurgitation was successfully
met in 92% of device patients. There were no device frac-
tures or separations, but 1 death, 1 myocardial infarction,
and 1 case of device migration. The MONARC program
was discontinued owing to slow trial enrollment.15
Preliminary results from the TITAN study using the CDI
Carillon, recapturable, nitinol, self-expanding anchor, coro-
nary sinus annuloplasty device (Cardiac Dimensions, Inc,
Kirkland, Wash) enrolled 65 patients of whom 53 qualified
for device implantation. Thirty-six (68%) were success-
fully implanted, with the remainder not implanted owing
to either coronary artery compromise (8/53) or failure to
reduce mitral regurgitation (9/53). Follow-up at 30 days
demonstrated a 1.9% death rate and a wireform fracture
rate of 22%. Among those able to receive a device, there
was a mean 40% reduction in quantitative measures of
mitral regurgitation as well as reductions in NYHA class
and improvements in left ventricular remodeling, which
persisted at 1 year.16
Preliminary results from the PTOLEMY 2 study using
the Viacor PTMA system (Viacor, Inc, Wilmington,
Mass) of 37 patients; 33 had attempted implants, of which
27 (82%) were successful. Mortality in the implanted
patients was 22.2% (6/27 patients).17
Direct annuloplasty devices and other concepts. Several
devices were reported to have ‘‘first-in-man’’ safety andrdiovascular Surgery c Volume 142, Number 2 469
Meeting Proceedings Sun et alfeasibility studies underway including the Mitralign Direct
Annuloplasty System (Mitraling, Inc, Tewksbury, Mass),18
the GDSAccucinch System (Guided Delivery Systems, Inc,
Santa Clara, Calif),19 and the ReCor System (Ultrasound
Therapy; ReCor Medical, Ronkonkoma, NY).20
The MiCardia Adjustable Mitral Ring (MiCardia Corpo-
ration, Irvine, Calif) was presented as an investigational
device, which is an annuloplasty ring that is inserted surgi-
cally. The ring itself contains electrodes attached to a lead
that is placed subcutaneously and can be retrieved postoper-
atively so that radiofrequency energy can be applied, caus-
ing the ring to tighten.21
Another concept presented was the mitral spacer concept,
whereby a balloon is implanted to the left ventricle, tethered
to the apex, and provides additional coaptation surface be-
tween the mitral valve leaflets. This remains in preclinical
testing.22
Edge-to-edge repair. In the United States, the MitraClip
device (Abbott Laboratories, Abbott Park, Ill) continues
to be implanted as part of the REALISM continued access
registry after the EVEREST II randomized clinical trial.
Several subgroup analyses from EVEREST II were pre-
sented at TCT and this device remains in the forefront of
current transcatheter mitral repair technologies, having
achieved CE mark in Europe in March 2008. Glower23
reported that surgery after failed MitraClip insertion was
successful up to 5 years after the initial procedure and did
not differ in safety or efficacy from those patients random-
ized to initial surgery. In addition, prior MitraClip insertion
did not appear to predispose to a higher likelihood of valve
replacement versus repair.Mitral Valve Replacement
Still in its investigational stage, the ValveXchange device
(ValveXchange, Inc, Aurora, Colo) is made up of 2 compo-
nents: the Vitality valve (bovine pericardium) within the
Vanguard base or stent. The valve can be implanted via
a transapical, transcatheter technique, and the Vitality valve
itself can be removed from the Vanguard base/stent and
replaced with a new valve when needed.24 Several other
catheter-based mitral valve devices were presented, al-
though all remain in preclinical testing.25CORONARY REVASCULARIZATION
The SYNTAX trial randomized 1800 patients with left
main or 3-vessel coronary artery disease to either coronary
artery bypass grafting or percutaneous coronary interven-
tion. Three-year follow-up for the entire cohort was previ-
ously presented at the 2010 meeting of the European
Association for Cardio-Thoracic Surgery. At TCT, sub-
group analyses of patients with left main and 3-vessel
coronary artery disease within the SYNTAX trial were
presented. This showed no detectable difference between470 The Journal of Thoracic and Cardiovascular Surgcoronary artery bypass grafting (n¼ 348) and percutaneous
coronary intervention (n ¼ 357) in patients with left main
disease for the primary composite end point of major ad-
verse cardiovascular and cerebrovascular events (MACCE)
(22.3% vs 26.8%; P ¼ .2) nor the secondary end points of
death or myocardial infarction. There were significantly
more strokes in the coronary bypass group (4.0% vs
1.2%; P¼ .02) and a higher incidence of repeat revascular-
ization in the percutaneous coronary intervention group
(11.7% vs 20.0%; P<.01).26
In patients with 3-vessel coronary artery disease, coro-
nary bypass grafting (n ¼ 897) when compared with percu-
taneous coronary intervention (n ¼ 903) reduced MACCE
(18.8% vs 28.8%; P< .01), death (5.7% vs 9.5%; P ¼
.02), myocardial infarction (3.3% vs 7.1%; P<.01), and
need for repeat revascularization (10.0% vs 19.4%; P<
.01) with no detectable difference in stroke (2.9% vs
2.6%; P ¼ .64).27
THORACIC AORTIC ENDOGRAFT
The use of thoracic endografts was discussed for a num-
ber of challenging clinical scenarios. Dake28 presented
evidence supporting the use of endografts for complicated
type B dissection, traumatic disruption, and aortic rupture.
A number of next-generation devices were discussed, in-
cluding lower-profile 16F delivery systems, branched and
fenestrated graft designs, dissection-specific designs, and
ascending aortic devices.29
CONCLUSIONS
Although TCT continues to be a conference largely at-
tended by interventional cardiologists, its content is becom-
ing increasingly relevant to cardiac surgeons. In particular,
catheter-based valvular therapies are developing rapidly
largely owing to strong interest and enthusiasm from indus-
try, clinicians, and patients. The surgical presence and
participation at TCT has increased in recent years and has
been heralded by the initiation, in 2007, of a ‘‘TCT for
Surgeons’’ section at the meeting. This focuses on relevant
developments for the surgical community as well as on
training for transcatheter techniques and is now cospon-
sored by The American Association for Thoracic Surgery.
Undoubtedly, the relevance of the TCT content for cardiac
surgeons will continue to grow with the growth of catheter-
based therapies.
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